Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a ...

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...

It may be difficult for Sana to protect its technology from the prying eyes of other Pharma and biotech companies, using patents and maintaining a veil of secrecy. For me personally, however ...

On Wednesday, Sana Biotechnology shares received an upgrade from TD Cowen analysts, shifting from a Hold to a Buy rating. The upgrade was prompted by Sana's announcement of positive interim study ...

Since Sana released the data yesterday after market close, the biotech’s stock price has skyrocketed from $1.75 per share to $4.92 as of 10:30 a.m. ET today.

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according to ...